OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

SANOFI SA INHABER EO 2/  FR0000120578  /

gettex
04/10/2024  19:14:22 Chg. +0.900 Volume Bid19:30:49 Ask19:30:49 Market Capitalization Dividend Y. P/E Ratio
101.260EUR +0.90% 1,857
Turnover: 187,842.420		 101.100Bid Size: 99 101.260Ask Size: 99 127.52 bill.EUR 3.70% 23.60
GlobeNewswire 02/09 Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire 26/08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 14/08 Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire 13/08 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 12/08 MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire 12/08 MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
GlobeNewswire 08/08 Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire 06/08 Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire 05/08 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
GlobeNewswire 02/08 Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
GlobeNewswire 01/08 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 01/08 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 31/07 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire 25/07 Press Release: Online availability of Sanofi’s half-year financial report for 2024
TeleTrader 25/07 Europe lower premarket as earnings pour in
TeleTrader 25/07 Sanofi net sales up 7.8% to €10.7B in Q2
GlobeNewswire 25/07 Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire 24/07 US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire 18/07 Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire 17/07 Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire 12/07 FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire 11/07 Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire 08/07 Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...
GlobeNewswire 03/07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 03/07 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD